Fig. 4 | npj Breast Cancer

Fig. 4

From: Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer

Fig. 4

Immuno-FISH analysis of JAK2 copy number and phospho-STAT3. a Representative images of iFISH for pSTAT3 and JAK2 copy number at baseline and after cycle 2 in case 13. Scale bar 50  mm. b Maps showing topologic differences in the distribution of genetically and phenotypically distinct tumor cells based on their copy number signals for JAK2 and pSTAT3 in three different regions of the tumor. c Summary of cell type frequencies in all patients at baseline and after cycle 2. The graph depicts the mean percentage of each cell type in all areas and the samples are combined. p  < 0.0001 (Chi-square test). d Dot plot depicting the relative frequencies of the four different cell types at baseline and at cycle 2. The significance of the difference between baseline and cycle 2 samples was calculated using Wilcoxon rank-sum test. Error bars, S.E.M. e Shannon index of cellular diversity in matched baseline and cycle 2 samples for n  = 3 pairs 

Back to article page